Clinical trials
Large B-cell Lymphoma clinical trials
Below are recruiting large b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 393 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05800405RecruitingEarly Phase 1
Radiation before CAR T therapy for large B-cell lymphoma
This early-phase study tests whether giving targeted radiation first can improve outcomes when you later receive CAR T-cell therapy for large B-cell lymphoma that has come back or is not responding to treatment. It may help shrink or control lymphoma spots before CAR T is infused.
Duarte, CaliforniaAges 18 years+ - NCT05801913RecruitingPhase 1
Personalized immune cell therapy plus a CMV vaccine
This Phase 1 study tests genetically modified immune cells (made from your own blood) plus a vaccine aimed at controlling CMV-related lymphoma. It’s for adults with intermediate or high-grade B-cell non-Hodgkin lymphoma who can’t get (or don’t want) certain standard stem-cell transplant options.
Duarte, CaliforniaAges 18 years+ - NCT05826535RecruitingPhase 1/Phase 2
Test of CAR T-cell therapy for aggressive B-cell lymphoma
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
Irvine, CaliforniaAges 18 years+ - NCT05831865Recruiting
Testing best first-line stem cell transplant for aggressive lymphoma
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
Beijing, Beijing MunicipalityAges 18–70 - NCT05836896RecruitingPhase 1
Safety check of BCMA CAR T-cells made from your own immune cells
This early-phase trial tests whether a personalized BCMA-targeting CAR T-cell treatment is safe and what dose is tolerable in people whose lymphoma or myeloma has come back or did not respond to prior treatment. If you qualify, the team will monitor you closely for side effects to find the safest maximum tolerated dose.
DresdenAges 18 years+ - NCT05842707RecruitingPhase 1/Phase 2
Cord blood CAR cells for hard-to-treat B-cell lymphoma
This Phase 1/2 study tests cord blood–derived CAR NK cells that are designed to attack lymphoma cells marked with CD19 and/or CD70. It is for people whose B-cell non-Hodgkin lymphoma has come back or did not respond to prior treatment, including CAR-T when applicable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05852717RecruitingPhase 2
Epcoritamab plus GDP chemotherapy for relapsed large B-cell lymphoma
This Phase 2 study tests epcoritamab combined with GDP chemotherapy to treat adults whose large B-cell lymphoma has come back or did not respond to prior treatment. It aims to improve how safely and effectively the disease can be controlled after standard chemotherapy.
Indianapolis, IndianaAges 18 years+ - NCT05887167RecruitingPhase 1
Test safety of making CAR T cells from your own blood
This Phase 1 study looks at whether it is safe and practical to collect your own stem cells and use them to support CAR T-cell therapy for certain blood cancers that have come back or did not respond. It aims to find the best way to combine these steps, which may help some people receive CAR T treatment.
Los Angeles, CaliforniaAges 18–85 - NCT05890352RecruitingPhase 2
Add new medicines to standard treatment for returning lymphoma
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
Tucson, ArizonaAges 18 years+ - NCT05908409RecruitingPhase 1/Phase 2
Testing an investigational drug for blood cancers that came back
This Phase 1/2 trial tests IDP-121 in people with certain blood cancers that have returned or did not respond to available treatments. The goal is to find a safe dose and see whether the treatment can help control the cancer.
Santander, CantabriaAges 18 years+ - NCT05934084Recruiting
Lifestyle plan for heart and health after lymphoma remission
This trial tests a structured lifestyle and survivorship care plan for people who finished treatment for certain lymphoma types and are now in long-term remission. The goal is to support long-term health (including heart-related monitoring) and reduce future risks.
Ancona, AnconaAges 18–50 - NCT05940272Recruiting
Communication training for doctors treating large B-cell lymphoma
This study tests a communication training program for providers who care for people with large B-cell lymphoma. The goal is to improve how clinicians talk with patients, especially during difficult treatment periods like relapse.
New York, New YorkAges 18 years+ - NCT05952024RecruitingPhase 2
Acalabrutinib plus rituximab for older untreated DLBCL
This trial studies the combination of acalabrutinib and rituximab in older or frail people with newly diagnosed DLBCL (a type of lymphoma). It aims to see how well this treatment works and how safe it is for people who may not be able to tolerate standard chemotherapy.
Berkeley, CaliforniaAges 65–99 - NCT05991388RecruitingPhase 2/Phase 3
New treatments for children with relapsed B-NHL
This trial tests two new treatment combinations for children and young adults with B-cell non-Hodgkin lymphoma that has come back or not responded to previous therapy. The goal is to find better options for treating this cancer.
Sydney, New South WalesAges Up to 25 years - NCT06002659RecruitingPhase 1/Phase 2
CAR T therapy targeting CD20 for B-cell lymphoma
This study tests a new type of CAR T cell therapy that targets the CD20 protein on B-cell lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded to at least two previous treatments and who cannot use or have already tried the approved CD19 CAR T therapy.
StockholmAges Any age - NCT06005870RecruitingPhase 2
Zanubrutinib with R-CHOP for newly diagnosed p53-positive DLBCL
This trial tests a new combination: zanubrutinib (a targeted pill) plus standard chemotherapy (R-CHOP) for people newly diagnosed with DLBCL whose cancer cells have high p53 protein levels. The goal is to see if adding this drug helps shrink tumors better than chemotherapy alone.
Wuhan, HubeiAges 18–75 - NCT06015880RecruitingPhase 1
Combination drug therapy for relapsed or resistant large B-cell lymphoma
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06026488Recruiting
Study of DLBCL by genetic subtype
This study looks at how different genetic types of diffuse large B-cell lymphoma (DLBCL) respond to treatment in real-world settings. It may help doctors understand which treatments work best for your specific subtype.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06026319RecruitingPhase 1
CAR T cells targeting CD79b and CD19 for non-Hodgkin lymphoma
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It's for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments.
Boston, MassachusettsAges 18 years+ - NCT06043011Recruiting
Registry for non-Hodgkin lymphoma patients on systemic therapy
This registry tracks people with non-Hodgkin lymphoma who are starting a new line of systemic therapy. It collects information to better understand how treatments work in real life, and optionally asks you to fill out surveys about your symptoms and quality of life.
Freiburg im BreisgauAges 18 years+ - NCT06045910RecruitingPhase 1/Phase 2
A study of ALETA-001 for certain B-cell blood cancers
This trial tests a new treatment called ALETA-001 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments, including CAR T-cell therapy. It aims to see if ALETA-001 can help when standard options have not worked.
BirminghamAges 16 years+ - NCT06047197RecruitingPhase 1
RC19D2 cell therapy for advanced large B-cell lymphoma
This trial tests a new cell therapy called RC19D2 for people with diffuse large B-cell lymphoma that has not responded to standard treatments. The therapy uses your own immune cells that are modified to target and kill cancer cells.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06050694RecruitingPhase 2
Testing glofitamab plus chemo for untreated DLBCL
This trial tests a new drug called glofitamab combined with standard Pola-R-CHP chemotherapy for people with untreated DLBCL. The goal is to see if using PET scans and blood tests early on can guide treatment and improve outcomes.
Toronto, OntarioAges 18 years+ - NCT06081478RecruitingPhase 2
Targeted CAR-T cell therapy for advanced lymphoma or leukemia
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
Beijing, Beijing MunicipalityAges 14–85
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for large b-cell lymphoma?
- Yes. Clin2 currently lists 393 recruiting large b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a large b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a large b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Primary Mediastinal Large B Cell Lymphoma
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma Relapsed
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.